The primary treatment for parenchymal lung disease due to sporadic LAM is sirolimus, an inhibitor of the mTOR signaling pathway, which has been shown to reduce loss of lung function, chylous accumulation, and angiomyolipoma growth [7,10]. Here, MTOR is linked to angiomyolipoma.